Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DOXY 100.
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subcitrate potassium forms a protective coating on gastric mucosa, binds to bile acids, and has antibacterial activity against Helicobacter pylori. Metronidazole inhibits nucleic acid synthesis by disrupting bacterial DNA, while tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
For Helicobacter pylori eradication: 1 tablet (bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg) orally 4 times daily (with meals and at bedtime) for 14 days, plus a proton pump inhibitor.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Metronidazole: 8 hours (range 6-10), prolonged in hepatic impairment; Tetracycline: 6-11 hours (normal renal function), 57-120 hours in anuria; Bismuth subcitrate: negligible systemic absorption, elimination follows transit (~24-72 hours).
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Metronidazole: 60-80% renal (as unchanged drug and metabolites), 6-15% fecal; Tetracycline: 60% renal (glomerular filtration), 40% fecal (biliary and unabsorbed); Bismuth subcitrate: >99% fecal as insoluble bismuth sulfide.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic